Metabolic effects of olanzapine in patients with newly diagnosed psychosis

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 154-159

  Fernandez Egea, Emilio ^a   Miller, Brian ^b   Garcia Rizo, Clemente ^c   Bernardo, Miguel ^d,e,f   Kirkpatrick, Brian ^g  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^g TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

diabetes; family history; olanzapine; psychosis

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIPOLAR I DISORDER; BODY MASS; BRIEF PSYCHOTIC DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DELUSIONAL DISORDER; DIET RESTRICTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADOLESCENT; ADULT; BENZODIAZEPINES; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 79952441523     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820fcea3     Document Type: Article

References (27)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
2. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry. 2004;37(1):1-11. (Pubitemid 38230734)
3. Al-Janabi I, Arranz MJ, Blakemore AI, et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet. 2009;19:305-311.
4. Clark D, Skrobot OA, Adebiyi I, et al. Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. Eur Psychiatry. 2009;24:456-463.
5. Dickerson F, Rubalcaba E, Viscidi R, et al. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. Schizophr Res. 2008;104(1-3):121-126.
6. Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289-304. (Pubitemid 41044270)
7. Reaven GM, Lieberman JA, Sethuraman G. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res. 2009;43(11):997-1002.
8. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999;156:79-87. (Pubitemid 29034883)
9. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86:234-243. (Pubitemid 44251272)
10. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. (Pubitemid 47121394)
11. Fernandez-Egea E, Bernardo M, Parellada E, et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res. 2008;103(1-3):110-113.
12. Fernandez-Egea E, Miller B, Bernardo M, et al. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res. 2008;98(1-3):302-306. (Pubitemid 350245597)
13. Fernandez-Egea E, Bernardo M, Donner T, et al. The metabolic profile of antipsychotic-naBve patients with nonaffective psychosis. Br J Psychiatry. 2009;194(95):434-438.
14. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54(suppl 2): S114-S124.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62-S69.
16. Hollingshead AB, Redlich FC. Social Class and Mental Illness. New York: Wiley; 1958:387-397.
17. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry. 2006;67:1511-1521. (Pubitemid 44787432)
18. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients [letter]. Lancet. 1989;1(8636):495. (Pubitemid 19063553)
19. Spelman LM, Walsh PI, Sharifi N, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24(5):481-485. (Pubitemid 46669314)
20. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
21. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry. 2006;67: 1253-1260. (Pubitemid 44439698)
22. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005;162:118-123. (Pubitemid 40095680)
23. Lieberman JA, Tollefson G, Tohen M, et al; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404. (Pubitemid 41070913)
24. Sengupta SM, Klink R, Stip E, et al. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr Res. 2005;80:131-133. (Pubitemid 41587471)
25. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006;186:572-578.
26. Perez-Iglesias R, Mata I, Pelayo-Teran JM, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naBve population. Schizophr Res. 2009;107(2-3):115-121.
27. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131. (Pubitemid 47529346)